Abi-Dargham, A., et al. 1998. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. American Journal of Psychiatry 155(June):761-767. Available at http://ajp.psychiatryonline.org/cgi/content/full/155/6/761. Carlsson, A. 2001. A paradigm shift in brain research. Science 294(Nov. 2):1021-1024. Abstract available at http://www.sciencemag.org/cgi/content/abstract/294/5544/1021. Carpenter, W.T., and J.M. Gold. 2002. Another view of therapy for cognition in schizophrenia. Biological Psychiatry 51(June 15):969-971. Abstract available at http://dx.doi.org/10.1016/S0006-3223(02)01399-9. Hirvonen, J., et al. 2005. Increased caudate dopamine D₂ receptor availability as a genetic marker for schizophrenia. Archives of General Psychiatry 62(April):371-378. Abstract available at http://archpsyc.ama-assn.org/cgi/content/abstract/62/4/371. Miyamoto, S., et al. 2005. Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry 10(January):79-104. Reprint available at http://www.doctordeluca.com/Library/PsychoPharm/
Tx&MechanismSchizoReview05.pdf Seeman, P., and S. Kapur. 2000. Schizophrenia: More dopamine, more D₂ receptors. Proceedings of the National Academy of Sciences 97(July 5):7673-7675. Available at http://www.pnas.org/cgi/content/full/97/14/7673.